Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

Author:

Baden Lindsey R.ORCID,El Sahly Hana M.ORCID,Essink Brandon,Follmann DeanORCID,Hachigian Gregory,Strout Cynthia,Overcash J. Scott,Doblecki-Lewis SusanneORCID,Whitaker Jennifer A.,Anderson Evan J.ORCID,Neuzil KathleenORCID,Corey LawrenceORCID,Priddy Frances,Tomassini Joanne E.ORCID,Brown Mollie,Girard Bethany,Stolman Dina,Urdaneta Veronica,Wang Xiaowei,Deng Weiping,Zhou Honghong,Dixit AvikaORCID,Das Rituparna,Miller Jacqueline M.,

Abstract

AbstractPrimary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across 99 U.S. sites. The open-label (Parts B and C) primary objectives were evaluation of long-term safety and effectiveness of primary vaccination plus a 50-µg booster dose; immunogenicity was a secondary objective. Of 29,035 open-label participants, 19,609 received boosters (mRNA-1273 [n = 9647]; placebo-mRNA-1273 [n = 9952]; placebo [n = 10] groups). Booster safety was consistent with that reported for primary vaccination. Incidences of COVID-19 and severe COVID-19 were higher during the Omicron BA.1 than Delta variant waves and boosting versus non-boosting was associated with a significant, 47.0% (95% CI : 39.0-53.9%) reduction of Omicron BA.1 incidence (24.6 [23.4 − 25.8] vs 46.4 [40.6 − 52.7]/1000 person-months). In an exploratory Cox regression model adjusted for time-varying covariates, a longer median interval between primary vaccination and boosting (mRNA-1273 [13 months] vs placebo-mRNA-1273 [8 months]) was associated with significantly lower, COVID-19 risk (24.0% [16.0% − 32.0%]) during Omicron BA.1 predominance. Boosting elicited greater immune responses against SARS-CoV-2 than primary vaccination, irrespective of prior SARS-CoV-2 infection. Primary vaccination and boosting with mRNA-1273 demonstrated acceptable safety, effectiveness and immunogenicity against COVID-19, including emergent variants.

Funder

Moderna, Inc.

Publisher

Springer Science and Business Media LLC

Reference51 articles.

1. El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N. Engl. J. Med. 385, 1774–1785 (2021).

2. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

3. US Food and Drug Administration. Modenra TX Inc. SPIKEVAX (COVID-19 Vaccine, mRNA) Product Information. https://www.fda.gov/vaccines-blood-biologics/spikevax (2024).

4. European Union Medicines Agency. Moderna TX Inc. Spikevax (COVID-19 mRNA Vaccine) Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-moderna (2024).

5. World Health Organization. COVID-19 advice for the public: Getting vaccinated. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice (2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3